Report: AstraZeneca Eyes Acquisition Of Relypsa For $46 Per Share

Shares of Relypsa Inc (NASDAQ: RLYP) were trading higher by more than 2 percent at $28.60 early Thursday morning after the Daily Mail reported the company may be a potential acquisition target.

The Daily Mail reported that "rumors from across the Pond" suggest that AstraZeneca plc (ADR) (NYSE: AZN) is eyeing another acquisition just weeks after acquiring ZS Pharma. The publication suggested that the company's CEO Pascal Soriot "now wants to take out" Relypsa –- ZS Pharma's biggest competitor.